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R wave. For LBBB patients, however, there was substantial variability. In 45% of the
cases (15 of 33), the R wave did not coincide with onset of atrial motion.
Conclusion: In patients with a normal ECG, the onset of atrial motion has a predictable
relation with the R wave. In LBBB, this relationship is variable owing to QRS morphology
and electromechanical heterogeneity. In LBBB, atrial motion can be used to determine
time/degree zero because its union with the onset of systole is obligatory and because
EPI can reliably detect it. Setting the onset of the cardiac cycle to an "atriophasic" refer-
ence standard should prove useful in situations where the ECG is an unsuitable timing
signal.
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1133-154 Coronary Artery Magnetic Resonance Angiography 
Comparison of High Field Magnetic Resonance Imaging 
at 1.5 and 3 Tesla
Henning Steen, Joao A. C. Lima, Evangelos Giannitsis, Hugo A. Katus, Matthias Stuber, 
Johns Hopkins Hospital, Baltimore, MD, Universitätsklinikum, Klinik III, Heidelberg, 
Germany
Background:
Cardiac MRI examinations are currently performed at 1.5T. Yet, 3T MRI systems have
recently been approved for human use by the FDA. We compared objective and subjec-
tive parameters for coronary MRA image performance at both 1.5T and 3T.
Methods:
Twelve healthy adult subjects were scanned within one week on both a 1.5 and 3T whole
body scanner (Philips Intera) with an ECG and navigator gated fat suppressed T2 prep
3D gradient coronary MRA- (TR=8.2ms; TE=2.4ms, FOV=360; 512 matrix, 20 slices a
1.5mm, voxel-size= 0.7/1.0/3 mm) sequence. LAD and RCA vessel sharpness / diame-
ters were analysed semi-automatically. Fat saturation-, image quality and motion arte-
facts were assessed via consensus reading (1-4= poor to excellent image quality) and
evaluated using a two-tailed paired Student´s t-test.
Results:
On both scanners LAD and RCA coronary MRA could be successfully obtained. Vessel
sharpness was significantly improved at 3T (RCA: 63.24±0.24 vs. 40.77±0.04; LAD:
42.19±0.08 vs. 33.25±0, 04; both p<0.05) with insignificant difference in diameter com-
parison (RCA 1,5T= 2,85±0,24mm vs. 2,94±0,26 at the 3T; LAD at 1,5T= 2,96±0,27 vs.
2,81±0,25 at 3T). Fat saturation-, image quality and motion artefacts were not signifi-
cantly different.
Discussion:
Three Tesla Coronary MRA results in an objectively improved vessel sharpness and
diameter assessment when compared to 1.5T, while subjective parameters as navigator
and fat saturation performance were not affected by using higher magnetic field strength. 
1133-155 Phase Velocity Mapping by Cardiac Magnetic 
Resonance Is a Valuable Noninvasive Tool in the 
Assessment of Patients With Pulmonary Hypertension
Paola Kuschnir, Rafael Salguero, Javier Sanz, Teresa Rius, Roxana Sulica, Valentin 
Fuster, Michael Poon, Mount Sinai School of Medicine, New York, NY
Background: Advanced pulmonary hypertension is a disease with very poor prognosis.
Right heart catheterization (RHC) is currently the gold standard for its diagnosis. Phase
velocity mapping (PVM) by cardiac magnetic resonance (CMR) is a well-established
method to quantify pulmonary artery (PA) flow velocities. The purpose of our study was
to assess the correlation between hemodynamic data obtained by PVM with RHC.
Methods: 20 consecutive patients were referred for pulmonary hypertension evaluation
with CMR. Right ventricle ejection fraction was assessed by prospective triggered fast
imaging with steady-state precession sequence. PVM of PA was acquired with a breath-
hold, 2D segmented gradient-echo fast low-angle shot pulse sequence with retrospective
cardiac gating. All patients underwent RHC within one week to assess mean PA pressure
(MPAP, mmHg), right atrium pressure, PA saturation, PA vascular resistance index and
cardiac output by thermodilution. Correlations between PVM and RHC hemodynamics
were performed with Pearson’s linear coefficient. Cardiac output results were compared
with paired t-test.
Results: Average PA flow velocity (APV, cm/s) by PVM showed very good correlation
with MPAP (r=-0.86). APV values over 15 were found in all patients with MPAP under 25
(n=5). AVPAFV results between 10-15 were observed in those (n=6) with MPAP between
25-45 except one with an APV values of 9.85. APV values under 10 were found in all
patients (n=9) with MPAP>=45 except in one with an APV value of 10.03. APV value also
showed good correlation with PA vascular resistance index (r=-0.87), right ejection frac-
tion (r=0.83) and PA saturation (r=0.61). No significant correlations were observed for
peak PA flow velocity and forward volume by PVM with RHC data. Cardiac output (L/min)
assessed by PVM (5.34+/-1.50) was significantly lower than by RHC (6.28+/-
2.13)(P=0.047, r=0.45). The use of background suppression does not affect the results
significantly.
Conclusions: PVM can be clinical useful in the initial and follow-up evaluation of patients
with pulmonary hypertension. APV as assessed by PVM shows good correlation with
most RHC data and may be used as a non-invasive parameter in these patients.
1133-156 Results of Four Multicenter, Phase III, Magnetic 
Resonance Angiography (MRA) Trials With MS-325, a 
Blood Pool Contrast Agent, for the Detection of 
Vascular Disease in the Aortoiliac, Renal, and Pedal 
Regions
Emile R. Mohler, III, The MS-325-12/-13/-14/-15 Trial Investigators, University of 
Pennsylvania, Philadelphia, PA, EPIX Medical, Cambridge, MA
Background: To evaluate the safety and efficacy of MS-325 for contrast enhanced (CE)
MRA in the Aortoiliac, Renal, and Pedal arteries as compared to non-contrast 2D-TOF
MRA, using catheter angiography (XRA) as the standard of reference (SOR) in adult
patients with known or suspected arterial occlusive disease.
Methods: Patients received a 0.03 mmol/kg IV bolus of MS-325, an investigational MRI
blood pool contrast agent. In each study, two independent blinded readers interpreted all
XRA images for the presence of clinically significant (>50%) stenosis, with a third reader
independently reading in case of disagreement, in order to establish the SOR. Three dif-
ferent independent blinded readers separately interpreted 2D-TOF and CE-MRA image
sets. Sensitivity, specificity, and accuracy of diagnosis were evaluated for each blinded
reader. Vessels deemed uninterpretable in MRA were considered inaccurate. Inter-
reader XRA agreement was estimated by comparing the results of the two XRA readers.
Patient safety parameters were monitored for 72-96 hours post injection.
Results: Over the four trials, 641 patients and 3404 vessels were evaluated. On average,
MRA readers showed absolute improvements in sensitivity, specificity, and accuracy of
16.4%, 14.6%, and 13.9%, respectively with the application of MS-325. Each reader
showed improvement in accuracy; these improvements were statistically significant in 11/
12 readers. MS-325 gave significant improvements in specificity in all readers; the renal
and aortoilliac readers also showed significant sensitivity improvements. These values
for MS-325-enhanced MRA were comparable to that of XRA inter-reader agreement.
Rates of uninterpretable vessels were 1.6% in CE-MRA, 15.1% for TOF-MRA, and 9.5%
for XRA. Studies yielded consistent safety results: overall AE rate possibly or probably
related to MS-325 was 21%, of those, the majority (96%) were mild or moderate in sever-
ity. No adverse trends in lab chemistries or ECG results were observed.
Conclusion: In 4 Phase III studies, MS-325 was demonstrated to be safe and effective
for the MRA assessment of vascular disease in multiple vascular territories.
1133-157 Effect of Serum Cholesterol Levels on Coronary 
Vasoreactivity in Patients With Type II Diabetes Mellitus
Olakunle O. Akinboboye, Yi Wang, Khurram Moin, Sunil Mathew, Kathy McGrath, 
Margurite Roth, Dwaraka Pollepalle, Raplh Dim, Nathaniel Reichek, Saint Francis 
Hospital, Roslyn, NY
Introduction: Coronary endothelial function is often impaired in patients with diabetes
mellitus (DM). However the determinants of endothelial function in patients with DM have
not been clearly defined. e assessed the magnitude and determinants of myocardial
blood flow response to cold-pressor testing (CPT) using first-pass contrast-enhanced
MRI.
Methods: Twelve patients (5 females, mean age 59 ± 9 with DM but without overt CAD,
underwent MRI first-pass perfusion study at rest and following CPT). Imaging was per-
formed on a 1.5 T Siemens Sonata scanner (Siemens Medical Solutions, Malvern, PA),
using TurboFLASH sequence with the following parameters TR/TE/TI/FA/contrast dose/
data matrix/spatial resolution = 2.9ms/1.3ms/90ms/6°/0.05 mmol/kg/128x70/
3.5x1.9x8mm3. Using MEDIS software (Medis Imaging Systems Inc, The Netherlands),
the steepness of the first pass myocardial signal intensity curve's upslope, normalized to
blood pool upslope (relative upslope) with CPT was divided by corresponding baseline
measurement to calculate myocardial perfusion reserve index (MPRI). In addition the fol-
lowing serum assays were measured: total cholesterol (T chol), triglycerides (trig), HDL
cholesterol (HDL), LDL cholesterol (LDL), Fasting blood glucose (FBS), C-reactive pro-
tein (CRP), insulin, hemoglobin A1c (H-A1c), and Von-Willebrand factor (VWF). Urinary
microalbumin level (µalb), weight (Wt) and waist circumference (WC) were also mea-
sured.
Results: Mean weight 163 ± 55 lbs, µalb: 23 ± 32 mg/dl, WC= 106 ± 9 cm, Tchol= 192 ±
41, Trig = 177 ± 107 mg/dl, HDL= 42 ± 11 mg/dl , LDL= 114 ± 32 mg/dl, FBS = 148 ± 43
